<DOC>
	<DOCNO>NCT00926575</DOCNO>
	<brief_summary>Use oral topically-active glucocorticoid limited side effect control gastrointestinal inflammatory process GVHD minimize glucocorticoid exposure .</brief_summary>
	<brief_title>Study orBecÂ® With Prednisone Therapy Treatment Patients With Graft Versus Host Disease ( GVHD )</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Receipt allogeneic hematopoietic cell transplant Diagnosis GI graft vs. host disease ( GVHD ) No GI infection Must able swallow tablet Must able read understand inform consent Adequate birth control method duration study Significant Skin GVHD Liver GVHD Persistent vomit HIV positive Pregnancy/lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>BDP</keyword>
	<keyword>orBec</keyword>
	<keyword>GVHD</keyword>
	<keyword>beclomethasone dipropionate</keyword>
	<keyword>bone marrow transplant</keyword>
	<keyword>hematopoietic cell transplant</keyword>
	<keyword>HCT</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>marrow transplant</keyword>
	<keyword>SCT</keyword>
	<keyword>beclomethasone 17,21-dipropionate</keyword>
</DOC>